Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

ected food craving measures.

The overall discontinuation rate due to adverse events was 25.9% for patients taking Contrave versus 13.0% for those taking placebo. The most frequently observed adverse events leading to discontinuation for patients on study drug were nausea, urticaria (hives) and anxiety. The discontinuation rate due to nausea was 4.6%, an improvement over the 11.1% discontinuation rate seen in the Phase 2 trial (NB-201) which utilized the immediate release formulation of naltrexone as opposed to the proprietary SR formulation used in this trial. The most frequently observed treatment-emergent adverse events for patients on study drug were nausea, headache, constipation and dizziness.

"The results show that Contrave provided obese patients with clinically significant weight loss sustained over a one year period while also improving markers associated with cardiovascular disease," said Dr. Xavier Pi-Sunyer, a lead investigator for the study and Chief of Endocrinology at St. Luke's-Roosevelt Hospital/Professor of Medicine at Columbia University. "This study also showed that Contrave was generally well tolerated by patients, which is important in terms of patient compliance, especially since treating obesity is often a long-term endeavor."

The Company has scheduled a conference call at 5:00 pm Eastern Time to discuss further details from this trial. The live call may be accessed by calling 877-317-6701(domestic) 412-317-6701 (international); meeting code: 007 4510. The webcast can be accessed live on the investor relations section of the Company's web site at http://www.orexigen.com and will be archived for 14 days following the call. Additional findings will be presented at the JPMorgan Healthcare Conference on January 12, 2009 at 8:00 am (PST) in San Francisco, California.

About Obesity

Obesi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)... 2014 According to Jeff Howell, Partner ... ITRA Global, new development in Downtown Toronto is expanding ... approving another 755 storeys of new development last week ... will be dominating the Toronto skyline for the foreseeable ... unquenchable thirst for new development. , As the Toronto ...
(Date:9/15/2014)... SYDNEY , Sept. 15, 2014 ... focused on revolutionizing the treatment of cancer through ... cancer cells, announced that, together with the Asbestos ... 2014 Cancer Institute New South Wales (NSW) Premier,s ... other four recipients are the hospitals that will ...
(Date:9/15/2014)... Northeastern University has developed a novel method for ... of nanocarbon structures in carbon nanotube arrays. The ... allow the researchers to tailor the physical properties ... from electronic devices to CNT-reinforced composite materials found ... Their findings were published in the journal ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... France, April 23 , - ... Essilor International, the world leader in ophthalmic optics, today,announced ... 31, 2009, representing a reported 10.3% increase on the first ... the period. , Despite contracting demand ...
... RICHMOND, Calif., April 22 Sangamo BioSciences, Inc. (Nasdaq: ... will release its first quarter 2009 financial results on ... press release will be followed by a conference call ... the public via telephone and webcast. During the conference ...
... to Discuss Results to Be Held at 9:00 A.M. - ... VPHM ) first quarter financial results for 2009 are ... the open of the U.S. financial markets.The company will host ... Eastern Time on the same day. During the conference ...
Cached Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 3ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2
(Date:9/15/2014)... on Earth for the first 500 million years after ... present day, complete with oceans, continents and active crustal ... eon, called the Hadean, has gained substantial new support ... formed more than 4 billion years ago with those ... a possible geological analog for early Earth. , The ...
(Date:9/15/2014)... are hallmarks of the cheetah: The big predator is the ... mph in just a few seconds. As it ramps up ... bounding until it reaches a full gallop. , Now MIT ... implemented in a robotic cheetah a sleek, four-legged assemblage ... much as its feline counterpart. The team recently took the ...
(Date:9/15/2014)... who transplanted combinations of wild, domesticated, and ... to new environments found that within 5 ... foreign genes from wild populations that hybridized ... Applications study provides evidence that natural ... that hybridized populations experience as a result ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Run, cheetah, run 2Run, cheetah, run 3
... how the brain controls breathing is fundamental to the ... an automatic rhythmic process that persists without conscious effort ... that has intrigued many scientists for well over 100 ... rhythm throughout life? , Experimental Physiology editor Julian Paton ...
... sudden changes in water quality, creation of coastal "dead ... climate are just some of the potential consequences of ... new United Nations-backed report launched today. , Humans have ... 50 years than in any other period, some 60 ...
... can survive an otherwise lethal dose of vaccinia virus, ... the National Institute of Allergy and Infectious Diseases (NIAID), ... say the investigators, suggest that Gleevec or similar drugs ... smallpox vaccine. The classic smallpox vaccine is made from ...
Cached Biology News:How exactly does the brain control breathing? 2UN: World in big ecological mess 2UN: World in big ecological mess 3Cancer drug slows poxvirus in mice 2Cancer drug slows poxvirus in mice 3
... ChipReader systems are highly sensitive laser confocal ... These are advanced scanners that meet your ... background level, and optimizing the signal on ... end of the range for increased sensitivity. ...
Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... Hyb-Seal slide chambers are vapor-tight adhesive chambers for ... chambers are affixed over a sample on a ... of two ports, and the ports are then ... removed and replaced to allow exchange of reaction ...
... 3 nmol (individual) with sequence siTrio ... targeted to your target gene of interestis our ... get more than 75% knockdown of your target ... siRNA for transfection and confirmation of optimal transfection ...
Biology Products: